It was another busy week for Australia’s top brokers. This led to the release of a large number of broker notes.
Three ASX broker buy ratings that you might want to know more about are summarised below. Here’s why brokers think these ASX shares are in the buy zone:
AGL Energy Limited (ASX: AGL)
According to a note out of UBS, its analysts have retained their buy rating on this energy giant’s shares with a slightly reduced price target of $11.25. UBS was pleased with AGL’s first half result, noting that it was well ahead of the broker’s expectations. It sees potential for further earnings outperformance in the coming years if its generation availability can be maintained. The AGL share price ended the week at $8.63.
CSL Ltd (ASX: CSL)
A note out of Morgans reveals that its analysts have retained their add rating on this biotechnology giant’s shares with a trimmed price target of $315.40. This follows the release of a solid half-year result which revealed earnings ahead of consensus expectations. Overall, Morgans was pleased with the result and especially the performance of the key CSL Behring business. And although the broker has trimmed its valuation to reflect the CSL112 trial failure, it continues to see a lot of value on offer. The CSL share price was trading at $284.00 at Friday’s close.
Pro Medicus Limited (ASX: PME)
Analysts at Macquarie have retained their outperform rating and $120.00 price target on this health imaging technology company’s shares. Macquarie notes that Pro Medicus fell short of the broker’s first-half expectations with both its revenue and earnings. However, it remains positive given new contract wins and its healthy sales pipeline. The Pro Medicus share price was trading at $87.24 on Friday.
The post Top brokers name 3 ASX shares to buy next week appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now…
See The 5 Stocks
*Returns as of 10 November 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- If I could buy only one ASX stock this February earnings season, it would beâ¦
- Brokers name 3 ASX shares to buy now
- 7 ASX 200 shares with ex-dividend dates next week
- Why Inghams, IAG, Neuren Pharmaceuticals, and Pro Medicus shares are sinking today
- Top brokers name 3 ASX shares to buy today
Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Macquarie Group, and Pro Medicus. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended CSL and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/SY4IrWa
Leave a Reply